MSM Protein Seizes Russian Antibody Opportunity
This article was originally published in Start Up
Executive Summary
Benefiting from pharma's ongoing love affair with antibodies-illustrated most recently in Bristol-Myers Squibb's $2 billion purchase of Medarex--Boston-based start-up MSM Protein Technologies signed two drug discovery deals in late July.